FDA Breakthrough Device Designation

Precision at the speed of light.

AI + Imaging: guiding cancer surgery to better outcomes.

The problem

Today, surgeons learn the margin result days after the operation.

Pathology takes five to ten days. When the pathologist finds cancer at the edge of the removed tissue, the patient comes back for a second surgery.

23% of breast lumpectomies have a positive margin and need re-excision.1
$16k cost of the second operation for a breast lumpectomy patient.1
5 to 10 days from surgery to the pathology report that tells the surgeon whether cancer was left behind.

1. Metcalfe et al., JAMA Surg 2017;152(11):1084.

Why margins matter in breast surgery →

The product

LUCY provides the margin results in the operating room during the surgery.

From excised tissue to a map on the screen within two minutes.

The LUCY console: a wheeled cabinet with a specimen drawer, a touchscreen and an arm-mounted display showing the scan map.
LUCY, the ex vivo system for margin assessment
  1. 1

    Scan

    The specimen goes in the tray, the drawer closes, one button starts the scan.

  2. 2

    See

    In under two minutes a color-coded map shows where the surface carries the signature of cancer.

  3. 3

    Decide

    The surgeon takes more tissue from the flagged spot in the same session, or closes.

  4. 4

    Close

    A complete resection in the first operation, so fewer patients come back for a second.

No dye, no contact probe, no change to the surgical workflow.
Clinical proof: breast lumpectomy

≥90% sensitivity and specificity vs. histopathology.

Two breast lumpectomy slices, each shown three ways: the gross specimen, the LUCY classification map with cancer in yellow and red, and the H&E whole-mount slide.
Accuracy vs. histopathology
≥90% Sensitivity
≥90% Specificity

Results obtained using LUCY on slices from breast lumpectomy specimens.

50+patients
1,000+tissue slices
  • Accurate detection of breast cancer
  • Fast margin analysis in the OR
  • No specialist needed for interpretation; no workflow compromise

Investigational device Study results are from ex vivo clinical research and are not a substitute for FDA approval or clearance.